ArticleThe Journal of infectious diseases2022

Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.

Gabriela B Gomez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.